Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility and a connected person, rather than a comprehensive financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details specific share movements for an individual executive:
- Exercise of Options: Mrs. V A Whyte exercised a SAYE share option to purchase 1,009 Ordinary shares at a price of £9.51 per share (granted December 1, 2008).
- Gift Transfer: A transfer of 1,631 Ordinary shares was made by way of gift from Mrs. V A Whyte to her connected person, Mr. I Whyte.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is strictly a compliance notification under Disclosure Rule 3.1.4R(1)(a) and (c).
Investor Verification Points
- Verify the total shareholding of Mrs. V A Whyte and Mr. I Whyte following these transactions.
- Confirm the current market price of GSK Ordinary shares relative to the £9.51 exercise price mentioned.
- Review the company's annual Form 20-F for comprehensive financial performance data, as this 6-K does not contain it.